Rwanda
Tuberculosis profile
| High HIV burden |
Population  2013 12 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.81 (0.53–1.2) 6.9 (4.5–10)
Mortality (HIV+TB only) 0.49 (0.35–0.65) 4.2 (3–5.5)
Prevalence  (includes HIV+TB) 10 (7.6–14) 89 (65–117)
Incidence  (includes HIV+TB) 8.1 (7.3–9.6) 69 (62–82)
Incidence (HIV+TB only) 2.5 (2.2–2.9) 21 (18–25)
Case detection, all forms (%) 70 (59–79)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.9 (2.5–5.8) 19 (15–23)
MDR-TB cases among notified pulmonary
TB cases
170 (110–250) 96 (77–120)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 554   224
Pulmonary, clinically diagnosed 819    
Extrapulmonary 1 105    
       
Total new and relapse 5 702    
Previously treated, excluding relapses 278    
Total cases notified 5 980    
Among 5 702 new and relapse cases:
406 (7%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 275 (8%) 61 (12%) 1 060
Laboratory-confirmed RR-/MDR-TB cases     42
Patients started on MDR-TB treatment     43
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 882 (98)
HIV-positive TB patients 1 447 (25)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 384 (96)
HIV-positive TB patients on antiretroviral therapy (ART) 1 142 (79)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012 79
HIV-positive TB cases, all types, registered in 2012 77
RR-/MDR-TB cases started on second-line treatment in 2011 91
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 1.3
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF 16
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 7.5
% Funded domestically 60%
% Funded internationally 40%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-29 Data: www.who.int/tb/data